Cholinesterase mediated metabolism. No data pointing to CYP-inducing properties.

(To be edited, initial data ST OCT 04) Carbamate type of cholinesterase inhibitor used in light to moderate Alzheimer´s disease. Rapidly (t/2 60 minutes)´metabolized by cholinesterase mediated hydrolysis to the decarbamylated metabolite. CYP-metabolism probably of small importance. No data pointing to CYP-induction or inhibition.

Uneventful use reported in 1 patient with acute porphyria.